Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amicus Therapeutics (FOLD) Other Non-Current Liabilities (2016 - 2025)

Amicus Therapeutics (FOLD) has disclosed Other Non-Current Liabilities for 16 consecutive years, with $8.6 million as the latest value for Q2 2025.

  • For the quarter ending Q2 2025, Other Non-Current Liabilities fell 33.22% year-over-year to $8.6 million, compared with a TTM value of $8.6 million through Jun 2025, down 33.22%, and an annual FY2024 reading of $7.1 million, up 9895.77% over the prior year.
  • Other Non-Current Liabilities was $8.6 million for Q2 2025 at Amicus Therapeutics, up from $7.1 million in the prior quarter.
  • Across five years, Other Non-Current Liabilities topped out at $27.3 million in Q2 2021 and bottomed at $71000.0 in Q4 2023.
  • Average Other Non-Current Liabilities over 5 years is $11.0 million, with a median of $9.0 million recorded in 2023.
  • The sharpest move saw Other Non-Current Liabilities skyrocketed 17972.29% in 2023, then tumbled 99.53% in 2024.
  • Year by year, Other Non-Current Liabilities stood at $20.3 million in 2021, then tumbled by 77.11% to $4.7 million in 2022, then plummeted by 98.48% to $71000.0 in 2023, then soared by 9895.77% to $7.1 million in 2024, then rose by 21.84% to $8.6 million in 2025.
  • Business Quant data shows Other Non-Current Liabilities for FOLD at $8.6 million in Q2 2025, $7.1 million in Q4 2024, and $71000.0 in Q3 2024.